31 completed, 6 withdrawn, 5 recruiting, 5 terminated. 16 Phase 2, 14 Phase 1, 10 Not applicable, 5 Early Phase 1, 4 Phase 3.
Follow Stage IV Ovarian Cancer: new trials by email Literature Review of Stage IV Ovarian Cancer trials Research Report on Stage IV Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer Epithelial Ovarian Cancer, Stage III Ovarian Cancer | Not yet recruiting | The First Hospital of Jilin University | 100 | 2024-03-20 | 2024-04-01 | |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer Cisplatin, No treatment - Stage III Ovarian Cancer, Stage IV Ovarian Cancer | Phase 3 | Recruiting | GOG Foundation | 220 | 2024-03-08 | 2026-04-16 |
| Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer Niraparib - Ovarian Cancer, Stage III Ovarian Cancer | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 40 | 2023-08-21 | 2023-11-22 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) Mind-body resilience training, Music therapy, Propranolol - Ovarian Cancer, Ovarian Carcinoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 35 | 2022-06-17 | 2026-07-01 |
| CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells - Stage IV Ovarian Cancer, Testis Cancer, Refractory | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 200 | 2022-06-01 | 2024-06-25 |
| Ask Questions (ASQ):Implementation of a Communication Intervention Behavioral Intervention - Stage II Breast Cancer, Stage III Breast Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 81 | 2021-08-25 | 2023-08-16 |
| Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy Prehabilitation - Ovarian Cancer, Stage III Ovarian Cancer | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 22 | 2019-12-16 | 2026-01-07 |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites Canady Helios Cold Plasma Scalpel - Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer | Not applicable | Unknown | Jerome Canady, M.D. | 20 | 2019-07-30 | 2021-08-09 |
| 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC) 18F-DCFPyL - Stage III Ovarian Cancer, Stage IV Ovarian Cancer | Not applicable | Completed | University Health Network, Toronto | 20 | 2019-04-01 | 2022-11-02 |
| Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Quality-of-Life Assessment, Questionnaire Administration - Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 50 | 2019-01-02 | 2026-08-21 |
| PET Imaging of Ovarian Carcinoma With 18F-FSPG (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG), Positron Emission Tomography, Laboratory Biomarker Analysis - Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer | Early Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2018-06-01 | 2018-06-06 | |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2017-12-08 | 2018-05-01 | |
| Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Early Phase 1 | Completed | Roswell Park Cancer Institute | 19 | 2017-11-06 | 2021-10-06 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer | Phase 2 | Terminated | University of Washington | 11 | 2017-04-03 | 2022-01-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-06-01 | 2017-04-24 | |
| Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis - HER2/Neu Positive, HLA-A2 Positive Cells Present | Phase 1 / Phase 2 | Completed | University of Washington | 22 | 2016-05-01 | 2024-06-06 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma | Early Phase 1 | Completed | Mayo Clinic | 2 | 2016-01-01 | 2019-06-06 |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis - Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2015-06-01 | 2016-02-17 | |
| Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis Culdocentesis, Vaginal Swab, Chromopertubation - Stage III Ovarian Cancer, Stage IV Ovarian Cancer | Not applicable | Terminated | Dana-Farber Cancer Institute | 5 | 2015-05-01 | 2020-05-04 |
Showing 20 of 52. Sign in to see all of them.
Ovarian Neoplasms (52) · Fallopian Tube Neoplasms (29) · Breast Neoplasms (9) · Brenner Tumor (7) · Carcinoma, Ovarian Epithelial (6) · Carcinoma, Renal Cell (5) · Urinary Bladder Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Melanoma (4) · Prostatic Neoplasms (4) · Stomach Neoplasms (4) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Pancreatic Neoplasms (3)
Adnexal Diseases (52) · Endocrine Gland Neoplasms (52) · Endocrine System Diseases (52) · Female Urogenital Diseases (52) · Female Urogenital Diseases and Pregnancy Complications (52) · Genital Diseases (52) · Genital Diseases, Female (52) · Genital Neoplasms, Female (52) · Gonadal Disorders (52) · Neoplasms (52) · Neoplasms by Site (52) · Ovarian Diseases (52) · Urogenital Diseases (52) · Urogenital Neoplasms (52) · Fallopian Tube Diseases (29)
Carboplatin (13) · Paclitaxel (11) · Taxes (8) · Bevacizumab (4) · Cisplatin (4) · Sirolimus (4) · Chemotherapy, Adjuvant (3) · Cyclophosphamide (3) · Disulfides (3) · Immunoglobulin G (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Cytoreduction Surgical Procedures (2) · Docetaxel (2) · temsirolimus (2) · 1,2-diaminocyclohexaneplatinum II citrate (1)
Gynecologic Oncology Group (13) · National Cancer Institute (NCI) (8) · Mayo Clinic (3) · Roswell Park Cancer Institute (3) · University of Washington (3) · Barbara Ann Karmanos Cancer Institute (2) · Gradalis, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · Swedish Medical Center (2) · Alliance for Clinical Trials in Oncology (1) · Burzynski Research Institute (1) · Dana-Farber Cancer Institute (1) · GOG Foundation (1) · Jerome Canady, M.D. (1) · Mercy Medical Center (1)
United States (43) · Canada (7) · Japan (2) · South Korea (2) · China (1)
Amit Oza (2) · Kunle Odunsi (2) · Matthew S. Block, M.D., Ph.D. (2) · Minal Barve, MD (2) · Saul Rivkin, MD (2) · Agustin Garcia (1) · Amy Tiersten (1) · Armando Sardi, M.D. (1) · Charles Loprinzi (1) · Daniel Renouf (1) · David Gershenson (1) · Don Dizon (1) · Dr. Allan Covens, MD (1) · Emese Zsiros, MD (1) · Frances Lewis (1)
PMID 19720923, PMID 21941283, PMID 22204724, PMID 23219660, PMID 23969788, PMID 24779680, PMID 25318437, PMID 25488966, PMID 26487588, PMID 29550184, PMID 30633128, PMID 30700568, PMID 31216226, PMID 31653510, PMID 34749008, PMID 35144591, PMID 35771552, PMID 36252167, PMID 36313720, PMID 36512649, PMID 37148580, PMID 37185961, PMID 37229879, PMID 37509349, PMID 37702588, PMID 38481806, PMID 40132910
U10CA027469 (11), U10CA180868 (5), N01CM62203 (3), P30CA015704 (3), N01CM00032 (2), N01CM00038 (2), N01CM00071 (2), N01CM62201 (2), N01CM62209 (2), P30CA015083 (2), P30CA016056 (2), R01CA158318 (2), U10CA101165 (2), N01CM00039 (1), N01CM00070 (1)